Phase 3 N=135 Clinical Study to Assess the Efficacy and Safety of DF277 Compared to Placebo in the Treatment of Otic Eczema
Otic Eczema
Primary: Analysis of the Itching Change at the End of Treatment. — -1.63; -1.25 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=121 Comparison of Two Needle Aspiration Techniques for Endoscopic Ultrasound-guided Fine Needle Aspiration (EUS-FNA) in Solid Pancreatic Lesions
Pancreatic Solid Lesions · Pancreatic Mass
Primary: Diagnostic Yield of Capillary Technique — 75.4 percentage of specimen
Phase 3 N=825 Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine
Acellular Pertussis · Tetanus · Diphtheria
Primary: Number of Seroprotected Subjects Against Diphtheria (D) and Tetanus (T) Toxoids — 241; 250; 234; 269 Participants
Phase 3 N=1,115 Radiation Therapy in Treating Patients With Stage II Prostate Cancer
Prostate Cancer
Primary: Five-year Disease-free Survival (DFS) Rate — 85.3; 86.3 percentage of participants — p=<0.001
Phase 3 N=689 Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612
Infections, Meningococcal
Primary: Number of Seroprotected Subjects Against the Vaccine Meningococcal Serogroups — 404; 132; 404; 131 Subjects
Phase 3 N=882 Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma
Asthma
Primary: Standardized Baseline-Adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time Zero to 12 Hours PostDose (FEV1 AUEC0-12) at Week 12…
Phase 3 N=614 A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Breast Cancer
Primary: Disease-free Survival — 88.6; 88.8; 87.1; 84.7 percentage of participants
Phase 3 N=10 Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma
Choroidal Melanoma
Primary: Mean Tumor Thickness — 2.91 mm
Phase 3 N=245 Evaluate Safety and Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine in Preterm Born Infants.
Infections, Streptococcal · Streptococcus Pneumoniae Vaccines
Primary: Number of Subjects Reporting Fever With Rectal Temperature Above (>) 39.0 Degrees Celsius (°C) — 8; 6 Subjects
Phase 3 N=787 Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma
Asthma
Primary: Standardized Baseline-Adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time Zero to 12 Hours Postdose (FEV1 AUEC0-12h) at Week 12…
Phase 3 N=497 Safety and Efficacy of Cariprazine for Bipolar I Disorder
Mania · Bipolar I Disorder
Primary: Change From Baseline in the Young Mania Rating Scale (YMRS) Total Score at Week 3 — -12.5; -18.6; -18.5 score on a scale — p=<0.001
Phase 3 N=395 An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants
Progressive Metastatic Prostate Cancer
Primary: Time to Prostate-specific Antigen (PSA) Progression — 8.31; 2.86 Months — p=<0.0001
Phase 3 N=24 Treatment of Adrenal Insufficiency in Children
Adrenal Insufficiency
Primary: Serum Cortisol Concentration up to 240 Minutes — 575.8 nmol/L
Phase 3 N=33 Octreotide in Treating Patients With Cancer-Related Malignant Ascites
Metastatic Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Median Time to Paracentesis — 28; 14 days — p=0.17
Phase 3 N=131 Depression in Alzheimer's Disease-2
Alzheimer's Disease · Depression
Primary: Modfied Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change (mADCS-CGIC) — 1; 0; 5; 2 participants — p=0.98